

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/911,692	Group Art Unit:	1644
Confirmation No.:	8484	Examiner:	R. Schwadron
Filed:	25 July 2001		
Applicant:	Darrell R. ANDERSON et al.		
For:	Expression and Use of Anti-CD20 Antibodies		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the documents listed on the Form PTO-1449 that accompanies this paper. Applicant does not represent that a search has been conducted or that the cited documents, copies of which (except for U.S. patent documents) are submitted with this paper, are prior art against the claims in this application.

This disclosure statement is filed before the mailing date of a first Office action on the merits under the provisions of 37 C.F.R. § 1.97(b)(3). Accordingly, applicant believes that no fee is due. The Director is requested to charge any fee that may be required to make this submission timely or proper to our Deposit Account No. 18-1260.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005
tel. (202) 736-8818
fax (202) 736-8711

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01009	Serial No:	09/911,692
	Inventor(s):	D.R. ANDERSON	Examiner:	R. Schwadron
	Filed:	25 July 2001	Art Unit:	1644

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	C1	2006/ 0034835 A1	16 Feb 06	Adams			

FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB	TRANSLATION
							YES
	C2	2004/ 056312	08 Jul 04	WO			NO

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	C3	Lowman, H.B. Slides presented at IBC Antibody Engineering Conference, 2 December 2003. Differential Activities in a Series of Humanized Anti-CD20 Antibodies.
	C4	Polyak, M.J., et al. (2002) <i>Blood</i> 99: 3256-62. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.

EXAMINER	
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 1 OF 1	